February 8, 2024 11:25 AM ESTUpdated 03:22 PM
Pharma

Wall Street: GLP-1 com­peti­tors’ pain is Eli Lil­ly’s gain

Max Gelman

Senior Editor

Eli Lil­ly’s stock con­tin­ued its wild ride Wednes­day af­ter lack­lus­ter da­ta from Am­gen’s po­ten­tial GLP-1 com­peti­tor fur­ther demon­strat­ed tirzepatide’s ad­van­tage.

On Wednes­day, Lil­ly shares …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

A service from the Financial Times